Multiple varieties, multiple technology platforms
Covers a variety of major diseases
Focus on First-in-class and
Best-in-class products
Real-time tracking and application of
advanced technologies,
Establish the underlying technology
transformation platform,
Establish a product pipeline with
core intellectual property rights
Layout | First-in-class、Best-in-class |
Property | Have core property rights and have a deep moat |
Tumor | Multiple varieties, 6 have been listed, 7 clinical and NMPA approval stages, 15 to be registered type test/clinical stage |
Internationally leading, complete categories, covering the entire process of tumor diagnosis. The main product lines include molecular (PCR, NGS), protein (Elisa, chemiluminescence, POCT), exosome (mRNA, miRNA and protein) |
|
Non-tumor | AD blood screen 5 test, AD cerebrospinal fluid 5 test, POCT 27 cytokine combination, liver status sH2a, hepatocyte injury ASGR1, early warning of nephropathy complicated FGF23, etc. |
Nucleic acid rapid detection products, such as new crown, Streptococcus pneumoniae, Chlamydia pneumoniae, HIV, etc. | |
Instrument | Mac-S POCT chemiluminescence instrument, single self-test or on-site molecular rapid detection equipment |